January 13, 2017New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
January 6, 2017Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
The Lancet Publishes Phase 2 Clinical Results Evaluating SPINRAZA in Patients with Infantile-Onset SMA
Ionis Pharmaceuticals Presents New Preclinical Data at the North American Cystic Fibrosis Conference
CHMP of the EMA has Granted Nusinersen Accelerated Assessment
Ionis Receives Drug Discovery Award to Support Cystic Fibrosis Research
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »
No upcoming events at this time...